[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342697-105":59,"doc-detail-342697-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-gene-therapy-the-safety-and-efficacy-of-systemic-delivery-of-a-new-liver-detargeted-tgf-signaling-inhibiting-adenovirus","Cancer Gene Therapy - The safety and efficacy of systemic delivery of a new liver-detargeted TGFβ signaling inhibiting adenovirus","","This article evaluates the safety and therapeutic efficacy of a newly engineered liver-detargeted adenovirus designed to inhibit TGFβ signaling in an immunocompetent triple negative mouse mammary tumor (4T1) model. The systemic delivery strategy addresses limitations of toxicity and viral clearance by using liver detargeting and enhanced tumor cell tropism. Results show reduced hepatic and systemic toxicity, increased Th1 cytokines, and anti-tumor cell populations, alongside significant suppression of lung metastasis, with further tumor growth inhibition when combined with anti-PD-1 and anti-CTLA-4.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-gene-therapy-the-safety-and-efficacy-of-systemic-delivery-of-a-new-liver-detargeted-tgf-signaling-inhibiting-adenovirus/342697/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-gene-therapy-the-safety-and-efficacy-of-systemic-delivery-of-a-new-liver-detargeted-tgf-signaling-inhibiting-adenovirus/342697.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are systemic adenoviral delivery routes challenging in metastatic TNBC?","Question",{"text":112,"@type":113},"Systemic administration increases liver/systemic toxicities, triggers quick viral clearance, and can limit tumor tropism, reducing effective delivery to metastatic sites.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the engineered liver-detargeted adenovirus (mHAdLyp.sT) address toxicity concerns?",{"text":117,"@type":113},"By incorporating liver detargeting and enhanced breast cancer cell tropism, systemic administration reduced hepatic and systemic toxicity in the 4T1 model.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune and anti-tumor effects were reported for mHAdLyp.sT?",{"text":121,"@type":113},"Systemic mHAdLyp.sT increased Th1 cytokines and anti-tumor cell populations, supported by cytokine analysis, spleen/tumor qRT-PCR, and flow cytometry.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342697,1790392594,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","[www.nature.com/cgt](www.nature.com/cgt) Cancer Gene Therapy  \nARTICLE OPEN   \nThe safety and efﬁcacy of systemic delivery of a new liver-detargeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary  \ntumor model  \nSoon Cheon Shin1,8, Renee E. Vickman 2,8, Bellur S. Prabhakar 7, Hans Schreiber6 and  \n© The Author(s) 2024  \nBeniamin Weidong  \nFilimon1, Yuefeng Yang  Xu 1 ✉  \n1,3, Zebin Hu1,4, Kathy A. Mangold5,6,  \n|  |  |  |\n| --- | --- | --- |\n|  | Aberrant TGFβ signaling is linked to metastasis and tumor immune escape of many cancers including metastatic triple negative breast cancer (mTNBC) . Previously, we have found that oncolytic adenoviruses expressing a TGFβ signaling inhibitory protein (sTGFβRIIFc) induced immune activation in a mouse TNBC (4T1) immunocompetent subcutaneous model with intratumoral injection. Systemic administration of adenoviruses can be a superior route to treat mTNBC but faces the challenges of increased toxicity and viral clearance. Thus, we created a liver-de-targeted sTGFβRIIFc- and LyP-1 peptide-expressing adenovirus (mHAdLyp.sT) with enhanced breast cancer cell tropism. Its safety and immune response features were proﬁled in the 4T1 model. Our data showed that the systemic administration of mHAdLyp.sT resulted in reduced hepatic and systemic toxicity. mHAdLyp.sT was also effective in increasing Th1 cytokines and anti-tumor cell populations by cytokine analysis, spleen/tumor qRT-PCR, and ﬂow cytometry. We further tested the therapeutic effects of mHAdLyp.sT alone and in combination with immune checkpoint inhibitors (ICIs) . mHAdLyp.sT alone and with all ICI combinations elicited signiﬁcant inhibition of lung metastasis by histological analysis. When mHAdLyp.sT was combined with both anti-PD-1 and anti-CTLA-4 antibodies, primary 4T1 tumor growth was also signiﬁcantly |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| inhibited. We are conﬁdent in advancing this new treatment option for mTNBC. |  |  |\n|  | Cancer Gene Therapy (2024) 31:574–585; [https://doi.org/10.1038/s41417-024-00735-1](https://doi.org/10.1038/s41417-024-00735-1) |  |\n|  |  |  |\n\nINTRODUCTION  \nTriple-negative breast cancer (TNBC) is a highly heterogeneous disease and often associated with a poor prognosis, particularly for patients diagnosed with late-stage metastatic cancers. Recent advances in immunotherapy with the development of immune checkpoint inhibitors (ICIs), have changed the treatment paradigm of TNBC, with new FDA approvals and many new clinical trials in progress [1–3] . Although current TNBC immunotherapy strategies are effective in early stage TNBC patients, only modest clinical responses are observed in patients with metastatic disease. This may be because late-stage tumors are often highly immunosuppressive, thus reestablishing a favorable immune environment; therefore, more effective and long-lasting anti-cancer responses with combination therapies is essential [3] . In recent years, many studies have shown that TGFβ signaling plays a central role in tumor immune evasion and resistance to ICIs [4, 5] . We have  \npreviously shown that tumor stromal expression of TGFβ-1 is associated with TNBC and is a poor prognostic marker of overall survival in breast cancer patients, which is consistent with other studies that linked TGFβ signaling to drug resistance and poor survival rate in TNBC patients [6–8]. Therapeutic strategies to block TGFβ signaling in advanced cancers by inhibitory antibodies or fusion proteins have been the focus of several clinical investigations, and some of them involve patients with metastatic TNBC (mTNBC) [9–11] . Thus, investigations combining TGFβ pathway  \ninhibitors with ICIs holds promise for the treatment of mTNBC.  \nWe previously reported that TGFβ blockade by direct inoculation of an oncolytic adenovirus expressing a fusion protein with soluble TGFβ receptor II and the human IgG F","cbCaitkHgePY80ln","https://ap.wps.com/l/cbCaitkHgePY80ln","pdf",1685062,12,"English","# Introduction\n## Background on TNBC and immunotherapy\n## Role of TGFβ signaling in immune evasion\n## Prior TGFβ blockade using oncolytic adenovirus\n## Rationale for systemic delivery and engineered adenovirus","[{\"question\":\"Why are systemic adenoviral delivery routes challenging in metastatic TNBC?\",\"answer\":\"Systemic administration increases liver/systemic toxicities, triggers quick viral clearance, and can limit tumor tropism, reducing effective delivery to metastatic sites.\"},{\"question\":\"How does the engineered liver-detargeted adenovirus (mHAdLyp.sT) address toxicity concerns?\",\"answer\":\"By incorporating liver detargeting and enhanced breast cancer cell tropism, systemic administration reduced hepatic and systemic toxicity in the 4T1 model.\"},{\"question\":\"What immune and anti-tumor effects were reported for mHAdLyp.sT?\",\"answer\":\"Systemic mHAdLyp.sT increased Th1 cytokines and anti-tumor cell populations, supported by cytokine analysis, spleen/tumor qRT-PCR, and flow cytometry.\"}]","Cancer Gene Therapy - The safety and efficacy of systemic delivery of a new liver-detargeted TGFβ signaling inhibiting adenovirus | PDF",1790047755,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d5250700dae45c40be06cc1b1f601f5.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfb3aa2e489ab8d44cb433d18263919e.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1c3f1d3ad3d5569dbbe8dddbb813385.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86c7e0bca18e46b292c8fa5532621a9e.webp",980,1301]